ATE548041T1 - Homoharringtonine allein oder in kombination mit anderen substanzen zur anwendung zur behandlung von chronischer myelogenischer leukemia resistent oder intolerant gegenüber proteinkinasehemmern ausgenommen sti 571 - Google Patents

Homoharringtonine allein oder in kombination mit anderen substanzen zur anwendung zur behandlung von chronischer myelogenischer leukemia resistent oder intolerant gegenüber proteinkinasehemmern ausgenommen sti 571

Info

Publication number: ATE548041T1
Authority: AT; Austria
Prior art keywords: treatment; myelogeneic; homoharringtonins; intolerant; chronic
Prior art date: 2001-09-05

Application number

AT09172828T

Other languages

English (en)

Inventor

Julie Blanchard

Francois-Xavier Mahon

Frederick Maloisel

Jean-Pierre Robin

Herve Maissonneuve

Original Assignee

Chemgenex Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-05

Filing date

2002-09-05

Publication date

2012-03-15

2002-09-05 Application filed by Chemgenex Pharmaceuticals Ltd filed Critical Chemgenex Pharmaceuticals Ltd

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE548041T1 publication Critical patent/ATE548041T1/de

Links

KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title abstract 2
229960002411 imatinib Drugs 0.000 title abstract 2
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
230000001684 chronic effect Effects 0.000 title 1
208000032839 leukemia Diseases 0.000 title 1
239000003909 protein kinase inhibitor Substances 0.000 title 1
239000000126 substance Substances 0.000 title 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
208000014767 Myeloproliferative disease Diseases 0.000 abstract 2
201000007224 Myeloproliferative neoplasm Diseases 0.000 abstract 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 abstract 1
HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 abstract 1
229960002230 omacetaxine mepesuccinate Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT09172828T 2001-09-05 2002-09-05 Homoharringtonine allein oder in kombination mit anderen substanzen zur anwendung zur behandlung von chronischer myelogenischer leukemia resistent oder intolerant gegenüber proteinkinasehemmern ausgenommen sti 571 ATE548041T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US31696701P	2001-09-05	2001-09-05

Publications (1)

Publication Number	Publication Date
ATE548041T1 true ATE548041T1 (de)	2012-03-15

Family

ID=23231501

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT02772653T ATE451106T1 (de)	2001-09-05	2002-09-05	Behandlung von sti571-resistenter oder - intoleranter chronischer myelogener leukemie mittels homoharringtonine alein oder in kombination mit anderen substanzen
AT09172828T ATE548041T1 (de)	2001-09-05	2002-09-05	Homoharringtonine allein oder in kombination mit anderen substanzen zur anwendung zur behandlung von chronischer myelogenischer leukemia resistent oder intolerant gegenüber proteinkinasehemmern ausgenommen sti 571

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT02772653T ATE451106T1 (de)	2001-09-05	2002-09-05	Behandlung von sti571-resistenter oder - intoleranter chronischer myelogener leukemie mittels homoharringtonine alein oder in kombination mit anderen substanzen

Country Status (12)

Country	Link
US (1)	US6987103B2 (de)
EP (2)	EP1443933B1 (de)
JP (2)	JP4794816B2 (de)
AT (2)	ATE451106T1 (de)
AU (1)	AU2002337410A1 (de)
CA (1)	CA2459822C (de)
CY (2)	CY1109799T1 (de)
DE (1)	DE60234708D1 (de)
DK (2)	DK1443933T3 (de)
ES (2)	ES2383771T3 (de)
PT (2)	PT1443933E (de)
WO (1)	WO2003020252A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6613753B2 (en) *	2001-02-21	2003-09-02	Supergen, Inc.	Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US6905669B2 (en)	2001-04-24	2005-06-14	Supergen, Inc.	Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6998391B2 (en) *	2002-02-07	2006-02-14	Supergen.Inc.	Method for treating diseases associated with abnormal kinase activity
US20040192652A1 (en) *	2002-12-06	2004-09-30	Giles Francis J.	Pharmaceutical combinations and methods for the treatment of leukemia
US20050037992A1 (en) *	2003-07-22	2005-02-17	John Lyons	Composition and method for treating neurological disorders
US20050059682A1 (en) *	2003-09-12	2005-03-17	Supergen, Inc., A Delaware Corporation	Compositions and methods for treatment of cancer
US7250416B2 (en) *	2005-03-11	2007-07-31	Supergen, Inc.	Azacytosine analogs and derivatives
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070117776A1 (en) *	2005-11-04	2007-05-24	John Lyons	Low Dose Therapy Of DNA Methylation Inhibitors
BRPI0710496A2 (pt) *	2006-04-07	2011-08-16	Novartis Ag	combinação que compreende a) composto de pirimidilaminobenzamida e b) inibidor de thr315iie cinase
EP2049096A4 (de) *	2006-08-02	2012-05-09	Univ South Florida	Verfahren zur behandlung chronischer myelogener leukämiezellen
AU2008240044B2 (en) *	2007-04-13	2013-09-12	Teva Pharamceuticals International Gmbh	Oral cephalotaxine dosage forms
EP2229160A1 (de) *	2007-12-07	2010-09-22	ChemGenex Pharmaceuticals, Inc.	Ablation von leukämie-stammzellen
JP5617175B2 (ja)	2008-04-17	2014-11-05	富士電機株式会社	ワイドバンドギャップ半導体装置とその製造方法
CN103619168B (zh) *	2011-06-29	2015-09-23	宾州研究基金会	用于治疗白血病的组合物、方法和药盒
HUE042327T2 (hu)	2011-08-30	2019-06-28	Astex Pharmaceuticals Inc	Decitabin-származék készítmények
WO2017004538A1 (en)	2015-07-02	2017-01-05	Otsuka Pharmaceutical Co., Ltd.	Lyophilized pharmaceutical compositions
BR112020002280A2 (pt)	2017-08-03	2020-07-28	Otsuka Pharmaceutical Co., Ltd.	composto farmacológico e métodos purificação do mesmo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030148955A1 (en) *	1999-04-19	2003-08-07	Pluenneke John D.	Soluble tumor necrosis factor receptor treatment of medical disorders

2002
- 2002-09-05 DE DE60234708T patent/DE60234708D1/de not_active Expired - Lifetime
- 2002-09-05 WO PCT/IB2002/003992 patent/WO2003020252A2/en not_active Ceased
- 2002-09-05 PT PT02772653T patent/PT1443933E/pt unknown
- 2002-09-05 EP EP02772653A patent/EP1443933B1/de not_active Expired - Lifetime
- 2002-09-05 DK DK02772653.8T patent/DK1443933T3/da active
- 2002-09-05 AU AU2002337410A patent/AU2002337410A1/en not_active Abandoned
- 2002-09-05 AT AT02772653T patent/ATE451106T1/de active
- 2002-09-05 AT AT09172828T patent/ATE548041T1/de active
- 2002-09-05 ES ES09172828T patent/ES2383771T3/es not_active Expired - Lifetime
- 2002-09-05 DK DK09172828.7T patent/DK2177223T3/da active
- 2002-09-05 ES ES02772653T patent/ES2334774T3/es not_active Expired - Lifetime
- 2002-09-05 PT PT09172828T patent/PT2177223E/pt unknown
- 2002-09-05 CA CA2459822A patent/CA2459822C/en not_active Expired - Fee Related
- 2002-09-05 JP JP2003524561A patent/JP4794816B2/ja not_active Expired - Fee Related
- 2002-09-05 EP EP20090172828 patent/EP2177223B9/de not_active Expired - Lifetime
2003
- 2003-03-27 US US10/397,267 patent/US6987103B2/en active Active
2009
- 2009-02-02 JP JP2009021692A patent/JP2009102408A/ja active Pending
2010
- 2010-02-10 CY CY20101100126T patent/CY1109799T1/el unknown
2012
- 2012-06-06 CY CY20121100501T patent/CY1112817T1/el unknown

Also Published As

Publication number	Publication date
HK1067562A1 (en)	2005-04-15
US6987103B2 (en)	2006-01-17
EP2177223A3 (de)	2010-05-19
DK1443933T3 (da)	2010-01-25
HK1143732A1 (en)	2011-01-14
PT1443933E (pt)	2010-01-27
WO2003020252A2 (en)	2003-03-13
EP1443933A2 (de)	2004-08-11
EP1443933B1 (de)	2009-12-09
CY1109799T1 (el)	2014-09-10
EP2177223B9 (de)	2012-10-31
CA2459822C (en)	2013-01-29
CY1112817T1 (el)	2016-02-10
DK2177223T3 (da)	2012-04-10
PT2177223E (pt)	2012-05-23
JP2009102408A (ja)	2009-05-14
AU2002337410A1 (en)	2003-03-18
CA2459822A1 (en)	2003-03-13
EP2177223B1 (de)	2012-03-07
ES2334774T3 (es)	2010-03-16
DE60234708D1 (de)	2010-01-21
EP2177223A2 (de)	2010-04-21
US20040019036A1 (en)	2004-01-29
ES2383771T3 (es)	2012-06-26
JP4794816B2 (ja)	2011-10-19
WO2003020252A3 (en)	2003-06-19
ATE451106T1 (de)	2009-12-15
JP2005508896A (ja)	2005-04-07

Similar Documents

Publication	Publication Date	Title
CY1112817T1 (el)	2016-02-10	Ομοχαρριγκτονινη μονη ή συνδυασμενη με αλλους παραγοντες για χρηση στην αγωγη της χρονιας μυελογενους λευχαιμιας, ανθεκτικης ή μη ανεκτικης σε αναστολεις πρωτεϊνικης κινασης εκτος του sτi 571
DE60031396D1 (de)	2006-11-30	Zubereitung zur behandlung von einer neurologischen erkrankung
DE60025812D1 (de)	2006-04-13	Jak-3 hemmer zur behandlung von allergischen störungen
DE69711034D1 (de)	2002-04-18	Wässrige fluorpolymerlösungen zur behandlung von harten oberflächen
ATE399553T1 (de)	2008-07-15	Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
EP1005345A4 (de)	2002-01-16	Methode und zusammensetzungen zur behandlung von allergischem asthma und anderen beschwerden mittels descarboethoxyloratadin
DE60103023D1 (de)	2004-06-03	Saure antimikrobielle zusammensetzungen zur behandlung von lebensmitteln und lebensmittel-kontaktflächen und verfahren zu ihrer anwendung
DE69833645D1 (de)	2006-04-27	Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen
DE602004005814D1 (de)	2007-05-24	Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
DE60330525D1 (de)	2010-01-28	Dynamische Anpassung einer Wegwerfschwelle zur fairen Behandlung von Multicast- und Unicastdatenrahmen
ATE209909T1 (de)	2001-12-15	Verwendung von tachykinin-antagonisten zur behandlung von erbrechen
EP1404871A4 (de)	2006-10-04	Methode zur behandlung von krebs im zusammenhang mit erhöhten her 2 werten
ATE312608T1 (de)	2005-12-15	Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom
DE69111457D1 (de)	1995-08-24	Katheter und vorrichtung zur behandlung, insbesondere von lungenembolien.
DE60206289D1 (de)	2006-02-02	Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
DE50108409D1 (de)	2006-01-19	Behandlung von oberflächen zur temporären verbesserung des schmutzablöseverhaltens
DE60210101D1 (de)	2006-05-11	Behandlung von haarfollikeln mit neurokinin 1 rezeptor antagonisten
DE69304843D1 (de)	1996-10-24	Methode zur Behandlung von Haarausfall
ATE427745T1 (de)	2009-04-15	Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
DE60206280D1 (de)	2006-02-02	Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
ATE347888T1 (de)	2007-01-15	Verwendung von aivlosin zur behandlung und prevention der lawsonia-infektionen in schweinen.
DE60144493D1 (de)	2011-06-01	Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE60109594D1 (de)	2005-04-28	R-eliprodil zur behandlung von glaucoma
ATE236633T1 (de)	2003-04-15	Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE602004016547D1 (de)	2008-10-23	1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen